Tazi, Yanis https://orcid.org/0000-0002-1595-9631
Arango-Ossa, Juan E.
Zhou, Yangyu
Bernard, Elsa https://orcid.org/0000-0002-2057-7187
Thomas, Ian
Gilkes, Amanda
Freeman, Sylvie https://orcid.org/0000-0003-1869-180X
Pradat, Yoann https://orcid.org/0000-0002-4647-5779
Johnson, Sean J.
Hills, Robert
Dillon, Richard https://orcid.org/0000-0001-9333-5296
Levine, Max F. https://orcid.org/0000-0001-5156-9086
Leongamornlert, Daniel https://orcid.org/0000-0002-3486-3168
Butler, Adam
Ganser, Arnold
Bullinger, Lars
Döhner, Konstanze https://orcid.org/0000-0002-2261-9862
Ottmann, Oliver
Adams, Richard https://orcid.org/0000-0003-3915-7243
Döhner, Hartmut https://orcid.org/0000-0003-2116-5536
Campbell, Peter J. https://orcid.org/0000-0002-3921-0510
Burnett, Alan K. https://orcid.org/0000-0003-1734-5817
Dennis, Michael
Russell, Nigel H.
Devlin, Sean M. https://orcid.org/0000-0002-6801-720X
Huntly, Brian J. P. https://orcid.org/0000-0003-0312-161X
Papaemmanuil, Elli https://orcid.org/0000-0003-1709-8983
Article History
Received: 10 February 2022
Accepted: 11 July 2022
First Online: 8 August 2022
Competing interests
: E.P. is a founder, equity holder and has a fiduciary role in Isabl, a cancer whole genome sequencing analytics company. The remaining authors declare no competing interests.